Javascript must be enabled to continue!
Psychometric Evaluation of PROMIS Sexual Function and Satisfaction Measures in a Longitudinal Population-Based Cohort of Men With Localized Prostate Cancer
View through CrossRef
AbstractBackgroundThere are multiple treatment options for men with localized prostate cancer that provide similar curative efficacy but differ in their impact on sexual functioning.AimTo evaluate the psychometric properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual Function and Satisfaction (SexFS) measures, including items from versions 1 and 2 of the short forms.MethodsA population-based cohort of men across North Carolina completed surveys via phone interviews at baseline (prior to treatment) and at 3, 12, and 24 months after cancer treatment initiation. Surveys included the PROMIS SexFS domains of interest in sexual activity, erectile function, orgasm, and satisfaction and the Prostate Cancer Symptom Indices. Analyses included descriptive statistics, assessment of structural validity using confirmatory factor analysis and item response theory, tests for differential item functioning, assessment of convergent validity using correlations, and evaluation of responsiveness of the PROMIS SexFS measures over time. We hypothesized that men undergoing surgery (prostatectomy) would report the poorest sexual function at the 3-month survey.ResultsSample size varied by assessment point and ranged from 332‒939 men, consisting of 30% non-white men, and 30% of the sample had a high school degree or less. The items within the PROMIS orgasm domain did not form a unidimensional scale. PROMIS measures of interest in sexual activity, erectile function, and satisfaction were unidimensional and highly correlated with related Prostate Cancer Symptom Indices measures (eg, erectile function, r = 0.84‒0.95). Erectile function in the surgery group declined more at 3 months compared to the no-surgery group (2 points); this difference narrowed at 12 and 24 months after surgery, as the surgery group recovered over time. Results were similar for PROMIS Interest in Sexual Activity and PROMIS Satisfaction scales.Clinical ImplicationsThe PROMIS SexFS measures may be used to identify effective interventions to treat sexual dysfunction and monitor sexual functioning in men with prostate cancer over time.Strength & LimitationsThis study was limited to men living in North Carolina who could self-report their health-related quality of life in English. However, this study was able to include more men from vulnerable populations by allowing them to self-report over the phone.ConclusionThis study provided strong support for use of the PROMIS SexFS (version 2) measures in men with localized prostate cancer to assess sexual interest, erectile function, and satisfaction over time.
Oxford University Press (OUP)
Title: Psychometric Evaluation of PROMIS Sexual Function and Satisfaction Measures in a Longitudinal Population-Based Cohort of Men With Localized Prostate Cancer
Description:
AbstractBackgroundThere are multiple treatment options for men with localized prostate cancer that provide similar curative efficacy but differ in their impact on sexual functioning.
AimTo evaluate the psychometric properties of the Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual Function and Satisfaction (SexFS) measures, including items from versions 1 and 2 of the short forms.
MethodsA population-based cohort of men across North Carolina completed surveys via phone interviews at baseline (prior to treatment) and at 3, 12, and 24 months after cancer treatment initiation.
Surveys included the PROMIS SexFS domains of interest in sexual activity, erectile function, orgasm, and satisfaction and the Prostate Cancer Symptom Indices.
Analyses included descriptive statistics, assessment of structural validity using confirmatory factor analysis and item response theory, tests for differential item functioning, assessment of convergent validity using correlations, and evaluation of responsiveness of the PROMIS SexFS measures over time.
We hypothesized that men undergoing surgery (prostatectomy) would report the poorest sexual function at the 3-month survey.
ResultsSample size varied by assessment point and ranged from 332‒939 men, consisting of 30% non-white men, and 30% of the sample had a high school degree or less.
The items within the PROMIS orgasm domain did not form a unidimensional scale.
PROMIS measures of interest in sexual activity, erectile function, and satisfaction were unidimensional and highly correlated with related Prostate Cancer Symptom Indices measures (eg, erectile function, r = 0.
84‒0.
95).
Erectile function in the surgery group declined more at 3 months compared to the no-surgery group (2 points); this difference narrowed at 12 and 24 months after surgery, as the surgery group recovered over time.
Results were similar for PROMIS Interest in Sexual Activity and PROMIS Satisfaction scales.
Clinical ImplicationsThe PROMIS SexFS measures may be used to identify effective interventions to treat sexual dysfunction and monitor sexual functioning in men with prostate cancer over time.
Strength & LimitationsThis study was limited to men living in North Carolina who could self-report their health-related quality of life in English.
However, this study was able to include more men from vulnerable populations by allowing them to self-report over the phone.
ConclusionThis study provided strong support for use of the PROMIS SexFS (version 2) measures in men with localized prostate cancer to assess sexual interest, erectile function, and satisfaction over time.
Related Results
Measuring patient-reported physical function and pain in total hip and knee arthroplasty
Measuring patient-reported physical function and pain in total hip and knee arthroplasty
Patient-Reported Outcome Measures (PROMs) are designed to capture patients’ perspectives in total hip arthroplasty (THA) and total knee arthroplasty (TKA). The recommended set of P...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract
Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
ImportanceAdvocates for removing the cancer label from grade group 1 (GG1) prostate cancer detected on biopsy primarily base their argument on the observation that when only GG1 is...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract
The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
What PROMIS Scores Correlate With Severe Disability in Cervical Spine Surgery?
What PROMIS Scores Correlate With Severe Disability in Cervical Spine Surgery?
Study Design:
Institutional Review Board-approved prospective cohort study.
Objectives:
To establish a conversion between ...
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract
BACKGROUND: Multiple steps and factors are involved in prostate carcinogenesis and tumor progression. The early studies have found that tumor-associated mac...
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...
Sequelae after multimodal treatment of rectal cancer
Sequelae after multimodal treatment of rectal cancer
<p dir="ltr">In recent decades, rectal cancer treatment has shifted from traditional surgical resection to include additional modalities such as radiotherapy and chemotherapy...

